BPC 157 5 mg — Selliza Pharma

BPC 157 5 mg Selliza Pharma

Selliza Pharma

€45,00

In Stock (100 available)

BPC 157 5 mg Selliza Pharma (5 mg) — Backed by Selliza Pharma’s commitment to quality, a revolutionary healing peptide derived from human gastric juice proteins. It dr…

100 in stock

5+ −10%

10+ −15% Best price

Third-Party Lab Report HPLC verified

CoA available on request — email support@vitalquests.org with the batch code from your vial.

HPLC TestedBatch report available

No Labels on BoxPlain brown parcel

Pay the CourierCash on delivery only

Ships TodayOrder before 14:00

€85+ = free shipping

EU warehouse — no customs, no delays

Tracked via DHL / DPD / InPost

Description

BPC 157 5 mg Selliza Pharma — BPC-157 from Selliza Pharma at 5 mg. Research peptide supporting tendon, ligament, and GI-lining repair. Local injection near the injury site amplifies effect.

Key Benefits

Tissue-repair peptide — gut, tendon, ligament, muscle
Synthetic fragment of body-protective compound from gastric juice
No HPTA effect, no aromatisation, no hepatotoxicity
Works systemically regardless of injection site
Stackable with any AAS cycle or standalone during recovery
Each unit dosed at 5 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: 250–500 mcg/day SubQ, split AM/PM for continuous coverage. Near-injury dosing sometimes preferred but systemic effect confirmed. Cycles 4–8 weeks for acute injury, up to 12 weeks for chronic tendinopathy.

How It Works

15-amino-acid synthetic fragment of body-protective compound (BPC) found in gastric juice. Mechanism: upregulates VEGF, promotes angiogenesis, accelerates fibroblast migration to injury sites, modulates nitric oxide pathways. Effective for gut, tendon, ligament, nerve, and muscle repair.

Pharmacokinetics

Plasma half-life approximately 4 hours. Once-daily dosing sufficient for most protocols; split AM/PM for continuous coverage on acute injuries. Reconstituted vial stable in fridge (2–8 °C) for 4–6 weeks.

Potential Side Effects

Very favourable safety profile. Mild injection-site irritation possible. No known systemic side-effects at research doses. No HPTA impact. No PCT required.

Cycle & Stacking Guide

Acute injury: 4–8 week course at 250–500 mcg/day. Chronic tendinopathy: 8–12 weeks. Stacks with TB-500 for broader healing synergy. Store lyophilised vial frozen; reconstituted vial fridge-only.

Manufacturer Notes

Selliza Pharma focuses on injectable blends with standardised concentrations. Tamper-evident vial caps; batch-date coded labels.

Storage & Handling

Lyophilised (freeze-dried) form: stable at 2–8 °C in the sealed vial for the duration printed on the label. After reconstitution with bacteriostatic water, store reconstituted solution at 2–8 °C and use within 30 days. Do not freeze reconstituted peptide — ice crystals denature the molecule. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “BPC 157 5 mg Selliza Pharma”

Complex peptide — 2D render unavailable. Reference via SMILES/InChI below.

Chemical Identity
#	CAS Registry Number	`137525-51-0`
Σ	IUPAC Name	L-Valyl-L-lysyl-L-lysylglycyl-L-alanylglycyl-L-seryl-L-threonyl-L-prolyl-L-cysteinylglycylglycyl-L-lysyl-L-leucine (pentadecapeptide BPC-157)
F	Molecular Formula	C₆₂H₉₈N₁₆O₂₂
M	Molecular Weight	1419.53 g/mol
△	Melting Point	N/A (peptide) °C
≋	Solubility	Soluble in water
t½	Biological Half-life	Estimated 4 hours

Pharmacological Profile
Aromatization	None
Hepatotoxicity	None

Clinical Notes

Mechanism & protocol-relevant pharmacology, reviewed by editorial pharmacology lead

Pentadecapeptide fragment of a human gastric juice protein (Body Protection Compound). Mechanism of action is incompletely characterised — documented effects include VEGFR-2 upregulation, NO-pathway modulation, and acceleration of tendon fibroblast proliferation in animal models. Human efficacy data is limited to case-series and off-label clinical reports; rigorous RCT data does not yet exist. Clinical picture consistent across anecdotal reports: accelerated soft-tissue healing (tendon, ligament) at 250–500 mcg/day subcutaneous; measurable effect on GI integrity (gastritis, inflammatory bowel reports). Site-specific subcutaneous injection close to the injury location is the empirical standard. Shelf-life post-reconstitution with bacteriostatic water is 4–6 weeks refrigerated. No documented side-effect profile at standard doses.

Known trade names: BPC-157, Body Protection Compound

External references

Wikipedia overview

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.

BPC 157 5 mg Selliza Pharma